Chemotherapy Induced Thrombocytopenia Therapeutics Market, By Drug Class (Thrombopoietin Receptor Agonists, Thrombopoietic Agents, and Others), By Route of Administration (Oral and Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmaci

Chemotherapy Induced Thrombocytopenia Therapeutics Market, By Drug Class (Thrombopoietin Receptor Agonists, Thrombopoietic Agents, and Others), By Route of Administration (Oral and Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Chemotherapy Induced Thrombocytopenia Therapeutics Market, By Drug Class (Thrombopoietin Receptor Agonists, Thrombopoietic Agents, and Others), By Route of Administration (Oral and Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Chemotherapy-induced Thrombocytopenia (CIT) is a prevalent medical condition associated with reduced chemotherapy doses, treatment interruptions, bleeding complications, and unfavorable outcomes in cancer patients. Currently, there exists a lack of well-defined guidelines for the prevention and management of CIT. In response to this challenge, thrombopoietin (TPO) replacement therapy has been developed and employed as an approach to address CIT by stimulating the production of megakaryocytes and expediting platelet generation. Despite platelet transfusions being the primary approach to managing severe CIT in cancer patients, there remain substantial unmet needs. These include persistently high rates of bleeding events and the necessity for adjustments or delays in anticancer therapy dosages.

Market Dynamics

The increasing number of pipeline products for the treatment of chemotherapy-induced thrombocytopenia is expected to drive the market growth. For instance, Nplate (Amgen Inc.) is a thrombopoietin receptor agonist (TPO-RA). It is being investigated in phase 3 for the treatment of chemotherapy-induced thrombocytopenia (CIT).

Thus, rising number of lead candidates in late phase clinical trial having the potential to gain regulatory approval is providing robust opportunities for pharmaceutical manufacturers to launch novel drugs for the treatment of CIT.

For instance, on October 19, 2020, Institute of Hematology & Blood Diseases Hospital initiated the single-arm study to evaluate the safety and efficacy of eltrombopag to treat chemotherapy-induced thrombocytopenia. The study is under Phase II trial and is expected to complete by December 2023.

Key features of the study:

• This report provides an in-depth analysis of the global chemotherapy-induced thrombocytopenia therapeutics market and provides market size (US$ Mn) and Compound Annual Growth Rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global chemotherapy-induced thrombocytopenia therapeutics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• The key companies covered as a part of this study include Amgen, Inc., Novartis AG, Pfizer Inc., Swedish Orphan Biovitrum AB, Jiangsu HengRui Medicine Co., Ltd., Teva Pharmaceutical Industries Ltd., and Mylan N.V.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global chemotherapy-induced thrombocytopenia therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chemotherapy-induced thrombocytopenia therapeutics market

Global Chemotherapy-induced Thrombocytopenia Therapeutics Market Detailed Segmentation:

• By Drug Class:
• Thrombopoietin Receptor Agonists
• Thrombopoietic Agents
• Others
• By Route of Administration:
• Oral
• Injectable
• By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• By Region:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East
• Africa
• Company Profiles
• Amgen, Inc.
• Novartis AG
• Pfizer Inc.
• Swedish Orphan Biovitrum AB
• Jiangsu HengRui Medicine Co., Ltd.
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.